comparemela.com

Page 5 - Beirut Medical Center News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Agios Announces Phase 3 ENERGIZE Study of Mitapivat Met Primary Endpoint and Both Key Secondary Endpoints in Adults with Non-Transfusion-Dependent Alpha- or Beta-Thalassemia

03.01.2024 - –Mitapivat Demonstrated a Statistically Significant Increase in Hemoglobin Response Rate Compared to Placebo – – Statistical Significance Also Achieved for Key Secondary Endpoints of Change From Baseline in Both FACIT-Fatigue Score and Hemoglobin . Seite 1

STAND Trial: Crizanlizumab Shows No Superiority Over Placebo for Sickle Cell Disease

The phase 3 STAND study contrasts from the phase 2 SUSTAIN study results, highlighting the absence of superiority of crizanlizumab over placebo on key efficacy endpoints.

Live :Wounds of War: The Gaza Experience Through the Eyes of Dr Ghassan Abu-Sitta

Wounds of War: The Gaza Experience Through the Eyes of Dr Ghassan Abu-Sitta

The Institute for Palestine Studies (IPS), in collaboration with the Global Health Institute (GHI) at the American University of Beirut (AUB) and the Arab Center for Research and Policy Studies (ACRPS), is honored to invite you to our upcoming event "Wounds of War: The Gaza Experience Through the Eyes of Dr. Ghassan Abu Sitta." The event will be livestreamed via IPS's English

The Destruction of Gaza s Health Sector: Confronting Devastation and Forced Displacement

The lecture will provide insight into Dr. Ghassan Abu-Sittah’s field experience during the ongoing genocidal war on Gaza as a firsthand witness to Israel’s systematic destruction of the health sector. The atrocities represent an attempt to ethnically cleanse Gaza and render it uninhabitable. Abu-Sitta will talk about the collective responsibility to prevent this from

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.